Region Uppsala, Sweden’s fourth largest healthcare region, has chosen to implement Stratipath Breast, an AI-based risk profiling solution for breast cancer, in clinical use.

Stratipath Breast will now be implemented into the routine diagnostic workflow in Region Uppsala for patients with early breast cancer, enabling treating physicians to make more informed treatment decisions based on fast and reliable AI-based prognostic risk profiling.

“This agreement with Region Uppsala shows that innovation in precision diagnostics is now being translated into real clinical benefit for patients,” said Fredrik Wetterhall, CEO and co-founder of Stratipath. “We’re proud that Stratipath Breast is being adopted as part of routine care, enabling faster, more equitable, and cost-effective cancer precision diagnostics.”

As one of Sweden’s largest and most research-intensive regions, Region Uppsala home to the well renowned Uppsala University Hospital  —has long stood at the forefront of medical innovation. By bringing Stratipath Breast into routine clinical practice, the region further strengthens its leadership  in digital pathology and precision oncology.

Stratipath Breast is the first CE-IVD marked AI-based solution for prognostic risk profiling of breast cancer using routine histopathology slides. It provides an alternative to traditional gene expression tests, which are often associated with high costs, long turnaround times, and limited accessibility. Stratipath Breast delivers results within one hour, ready to support clinical decisions at the tumour board.

Stratipath Breast enables healthcare providers to:
• Support treatment decisions with actionable risk profiling
• Make precision diagnostics available to more patients

“This clinical implementation reflects our core mission – to make precision diagnostics available to more patients,” said Prof. Johan Hartman, Chief Medical Officer and Co-founder of Stratipath. “With Stratipath Breast, we’re not only saving time and resources, we’re providing physicians with the tools they need to tailor treatments with greater confidence.”

A leading oncologist at Region Uppsala added: “We are excited to get started and hope that this implementation will allow us to offer prognostic risk assessment to more patients as part of routine care.”

This marks a significant step in the national initiative SwAIPP 2 (Sweden AI Precision Pathology), which aims to accelerate the transition of cutting-edge AI innovations into routine clinical care. The initiative is supported by the Swedish innovation agency Vinnova. The implementation in Region Uppsala demonstrates how innovative AI-based diagnostics can rapidly move from academic research into real-world clinical benefit, improving access to precision medicine for more patients.